

Scifinder and Thomson innovation

● 查詢步驟：

Research Topic "angiogenesis,colon cancer">references (30)>Colon cancer angiogenesis and antiangiogenic therapy >Index Term "Angiogenesis inhibitors" (8181)>keep analysis "CAS Registry Number" (1574)>Chemoprevention of colonic tum...>127464-60-2>commercial sources (20)>keep analysis "Catalog Name" (17)>Pierce Chemical Catalog



Explore ReferencesExplore SubstancesExplore Reactions

Welcome ChiHua Lu | Sign Out

Add KMP AlertResearch Topic "angiogenesis,colon cancer"

Saved Answer SetsKMP Alert ResultsNEW! SciPlannerHelpHistoryPreferences

Research Topic Candidates

5 Topics1 Selected

Select AllDeselect All

	Research Topic Candidates	References
☒	30 references were found containing "angiogenesis,colon cancer" as entered.	30
☐	4610 references were found containing both of the concepts "angiogenesis" and "colon cancer".	4610
☐	263659 references were found containing either the concept "angiogenesis" or the concept "colon cancer".	263659
☐	120990 references were found containing the concept "angiogenesis".	120990
☐	147279 references were found containing the concept "colon cancer".	147279

Get References

Contact Us | Copyrights and Trademarks

Copyright © 2011 American Chemical Society. All Rights Reserved.

[Return](#)

[Previous](#) | [Next](#)

16. Colon cancer angiogenesis and antiangiogenic therapy

By: Wray, Curtis J.; Rilo, Horatio L.; Ahmad, Syed A.

A review. Metastatic development is the primary cause of cancer treatment failure and is responsible for most deaths from colorectal cancer. For the majority of patients, by the time primary colorectal cancers are diagnosed, subclin. or clin. relevant liver metastases have already occurred. The formation of liver metastases represents a highly selective sequence in which a subpopulation of cells, within a tumor, express genes that allow them to progress through distinct steps and spread to distant organs. Modification of gene expression in these cells leads to transformation, growth, angiogenesis, invasion, dissemination, survival in systemic circulation, and attachment in the organ of metastases. Existing therapies directed at metastatic disease of the liver have had minimal impact on outcome. Contemporary treatment regimens are not likely to significantly alter the natural history of liver metastases. Consequently, understanding the mol. and biol. mechanisms of colorectal cancer may allow for the development of therapeutic strategies designed to prevent and treat liver metastases. Std. chemotherapy regimens have had only minimal success in effectively treating metastatic colorectal cancer. This review focuses on the mol. and biol. mechanisms of colorectal cancer angiogenesis. In addn., this report will evaluate the novel antiangiogenic therapeutic strategies targeting colorectal cancer and hepatic metastases.

Indexing

Pharmacology (Section 1-0)

Section cross-reference(s): 14

Concepts

AngiogenesisAngiogenesis inhibitorsHuman

colon cancer angiogenesis and antiangiogenic therapy

Source

Expert Opinion on Investigational Drugs
Volume 13
Issue 6
Pages 631-641
Journal; General Review
2004
CODEN: EOIDER
ISSN: 1354-3784
DOI: 10.1517/13543784.13.6.631

Company/Organization

Division of Surgical Oncology,
Department of Surgery
University of Cincinnati College of
Medicine
Cincinnati, OH, USA 45219

Accession Number

2004:438928
CAN 141:16733
CAPLUS

Publisher

Ashley Publications Ltd.

Language

● 論文摘要

Colon cancer angiogenesis and antiangiogenic therapy

A review. Metastatic development is the primary cause of cancer treatment failure and is responsible for most deaths from colorectal cancer. For the majority of patients, by the time primary colorectal cancers are diagnosed, subclin. or clin. relevant liver metastases have already occurred. The formation of liver metastases represents a highly selective sequence in which a subpopulation of cells, within a tumor, express genes that allow them to progress through distinct steps and spread to distant organs. Modification of gene expression in these cells leads to transformation, growth, angiogenesis, invasion, dissemination, survival in systemic circulation, and attachment in the organ of metastases. Existing therapies directed at metastatic disease of the liver have had minimal impact on outcome. Contemporary treatment regimens are not likely to significantly alter the natural history of liver metastases. Consequently, understanding the mol. and biol. mechanisms of colorectal cancer may allow for the development of therapeutic strategies designed to prevent and treat liver metastases. Std. chemotherapy regimens have had only minimal success in effectively treating metastatic colorectal cancer. This review focuses on the mol. and biol. mechanisms of colorectal cancer angiogenesis. In addition., this report will evaluate the novel antiangiogenic therapeutic strategies targeting colorectal cancer and hepatic metastases.

● 關鍵字查詢：angiogenesis inhibitor

利用其論文頁面的 index term: angiogenesis inhibitor 找到 8181 篇論文，再使用右邊欄位的 analysis 功能，以 CAS Registry number 為基準，搜索 127464-60-2 這個 substance.

會想使用 CAS Registry number 是因為這樣比較容易搜索出哪種是較為熱門的 substance。而我所選定的 127464-60-2 這個 substance 有 1574 篇論文。選定 <Chemoprevention of colonic tumorigenesis by dietary hydroxylated polymethoxyflavones in azoxymethane-treated mice> 這篇論文。

Welcome ChiHua Lu | Sign Out

Add KMP Alert Research Topic "angiogenesis,colon cancer" > references (30) > Colon cancer angiogenesis and ... > Index

Term "Angiogenesis inhibitors" (8181)

References Get Substances Get Reactions Get Related Tools NEW Send to SciPlanner

8181 References 0 Selected Save Print Export

1,574 references with the CAS Registry Numbers 127464-60-2 are displayed Keep Analysis Clear Analysis

Select All Deselect All Sort by: Accession Number Answers per Page [20] 1 2 3 4 5 6 ... 79 Display: [icon]

6. Chemoprevention of colonic tumorigenesis by dietary hydroxylated polymethoxyflavones in azoxymethane-treated mice
By Lai, Ching-Shu; Tsai, Mei-Ling; Cheng, An-Chin; Li, Shiming; Lo, Chih-Yu; Wang, Yu; Xiao, Hang; Ho, Chi-Tang; Wang, Ying-Jan; Pan, Min-Hsiung
From Molecular Nutrition & Food Research (2011), 55(2), 278-290. Language: English, Database: CAPLUS
Scope: Hydroxylated polymethoxyflavones (PMFs), existing exclusively in citrus genus, have been reported to exhibit a broad spectrum of biol. activity. Here we investigated the chemopreventive effects and underlying mol. mechanisms of dietary administration of hydroxylated PMFs in an azoxymethane (AOM)-induced colonic tumorigenesis model. Methods and results: Male, Institute of Cancer Research (ICR), mice at age of 6 wk were injected with AOM twice weekly at a dose of 5 mg/kg for 2 wk and continuously fed control diet or diets contg. 0.01 and 0.05% hydroxylated PMFs, resp. Mice were then sa...

35. Total surface coating of medical goods, especially implants with two layers
By Horres, Roland; Hoffmann, Michael; Linssen, Marita; Hoffmann, Erika; Caspers, Roger; Styrnik, Michaela
From Ger. Offen. (2006), DE 102005021622 A1 20061116. Language: German, Database: CAPLUS
The invention concerns the total surface coating of medical goods, esp. implants with two layers of coating; the first layer covers partially or totally the surface, including gaps, pores, openings etc.; the second layer covers completely the surface, including gaps, pores, openings etc. in a way that the coating forms a confluent layer on the medical good. Coating can be performed by spraying and dipping. Coatings are polymer based; they can include active substances. Coated medical goods are meshes, tubes, spiral shaped objects, stents, catheters, canules, implants, etc. Thus a stent was...

Substances Reactions ~1 Citing Full Text Link 0 Comments 0 Tags

Substances Reactions ~6 Citings Full Text Link 0 Comments 0 Tags

Analysis Refine

Analyze by: CAS Registry Number

Click bar to view only those references within the current answer set

CAS Registry Number	Count
127464-60-2	1574
33069-62-4	516
187888-07-9	458
106096-93-9	445
86090-08-6	410
50-35-1	383
23214-92-8	319
15663-27-1	304
129298-91-5	292
51-21-8	289

Vascular endothelial growth factor

Add KMP Alert Research Topic "angiogenesis,colon cancer" > references (30) > Colon cancer angiogenesis and ... > Index

Term "Angiogenesis inhibitors" (8181) > keep analysis "CAS Registry Number" (1574) > Chemoprevention of colonic tum... > 127464-60-2

Substance Detail Get References Get Reactions Get Commercial Sources Get Regulatory Info NEW Send to SciPlanner

CAS Registry Number: 127464-60-2

Unspecified

Vascular endothelial growth factor

Animal growth regulator, VEGF; Animal growth regulators, VEGF; Animal growth regulators, VEGF (vascular endothelial growth factor); Animal growth regulators, glioma-derived vascular endothelial growth factors; Cytokines, vascular permeability factor; FSDGF pituitary hormones; Folliculo-stellate-derived growth factors; Glioma-derived vascular endothelial growth factors; Pituitary hormones, folliculo-stellate-derived growth factors; VEGF; Vascular permeability factor; Vasculotropin

Manual Registration

Source of Registration: CA

~38,768 References

Document Types: Book, Conference, Dissertation, Journal, Patent, Preprint

CAS Role	Patents	Nonpatents	Nonspecific Derivatives from Patents	Nonspecific Derivatives from Nonpatents
Analytical Study	✓	✓	✓	✓
Biological Study	✓	✓	✓	✓

Substance Image Cannot Be Displayed 127464-60-2

最後知道 127464-60-2 這個 substance 就是 Vascular endothelial growth factor

Term "Angiogenesis inhibitors" (8181) > keep analysis "CAS Registry Number" (1574) > Chemoprevention of colonic tum... > 127464-60-2 > commercial sources (20) > keep analysis "Catalog Name" (17) > Pierce Chemical Catalog

Commercial Source Detail

[Link](#) | [Print](#) | [Export](#)

[Return](#) [Previous](#) | [Next](#)

1. Pierce Chemical Catalog

Catalog Information

Catalog Publication Date: 6 Jan 2011

Order Number: MA116626

Quantity: 100 µg, **Price:** \$343

Substance Information

CAS Registry Number: 127464-60-2

Chemical Name: Anti-Vascular Endothelial Growth Factor Monoclonal Antibody

Structure Image Not Available

Catalog Suppliers

Below are the contributing supplier(s) to this catalog.

Supplier Name	Address	Contact Information	Status
Thermo Fisher Scientific Brand: Pierce Chemical Pierce Chemical, part of Thermo Fisher Scientific	P O Box 117 Rockford, IL 61105 USA	Phone: 1-800-874-3723 Phone: +815-968-0747 (International) Fax: 1-800-842-5007 Fax: +815-968-4736 (International) Email: pierce.cs@thermofisher.com Web: http://www.thermofisher.com	Unclassified ▾

[Previous](#) | [Next](#)

● 查詢步驟 part-2 :

Research Topic "Anti-Vascular Endothelial Growth factor antibody, colon cancer">references (75)>keep analysis "CAS Registry Number" (40)>keep analysis "Document Type" (22)>patent

Scifinder 本身也有搜索專利的功能，因此決定直接利用 Scifinder 搜索專利。因為 Vascular Endothelial Growth factor 研究量較多，所以決定搜索 Angiogenesis inhibitor 中的 Anti-Vascular Endothelial Growth factor antibody 的專利

Preparation of human monoclonal anti-human vascular endothelial growth factor antibody for cancer therapy.



Europäisches Patentamt
European Patent Office
Office européen des brevets

Espacenet
Patent search

Deutsch English Français
Contact
Change country ▾

← About Espacenet Other EPO online services ▾

Search Result list ★ My patents list (0) Query history Settings Help

WO2011103702 (A1)

Bibliographic data

Description
Claims
Mosaics
Original document
Cited documents
Citing documents
INPADOC legal status
INPADOC patent family

Quick help
→ What does A1, A2, A3 and B stand for after a publication

Bibliographic data: WO2011103702 (A1) — 2011-09-01

★ In my patents list ↗ Register → Report data error [Print](#)

FULLY HUMAN MONOCLONAL ANTIBODY TO VEGF, PREPARATION METHOD AND USE THEREOF

Page bookmark WO2011103702 (A1) - FULLY HUMAN MONOCLONAL ANTIBODY TO VEGF, PREPARATION METHOD AND USE THEREOF

Inventor(s): WANG SHUHUI [CN]; LI CHUAN [CN]; KAN YING [CN]; TONG XIN [CN] ±

Applicant(s): BIOMAB PHARMACEUTICALS LTD [CN]; WANG SHUHUI [CN]; LI CHUAN [CN]; KAN YING [CN]; TONG XIN [CN] ±

Classification:
- International: A61K39/395; A61P35/00; C07K16/22; C12N15/13; C12N15/63
- European: C07K16/22

Application number: WO2010CN00513; 20100416

Abstract of WO2011103702 (A1)

Provided is a fully human monoclonal antibody to VEGF, the preparation method and use thereof. The fully human monoclonal antibody to VEGF is obtained by using the antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used for preparing the anti-tumor drug.

● 心得感想：

老實說，並不怎麼習慣去閱讀論文。但是這個搜索平台可以快速幫助使用者找到所要的東西。我認為單獨使用 Scifinder 比起搭配使用 Thomson innovation 這個專利檢索平台還要有效。所以這次報告就僅列出 Scifinder 的使用情形。

不過，僅單獨一堂課就要嫻熟這個平台還是略嫌倉卒了些。希望老師下次可以兩堂課都使用 scifinder，或是使用比較能多人同時使用的資料庫。這樣比較容易讓初學者能夠藉由互相討論而快速增加老師想傳達給我們的訊息。